Αποτελέσματα Αναζήτησης
19 Ιουν 2023 · Triple-negative breast cancer (TNBC) is a very heterogeneous and aggressive breast cancer subtype with a high risk of mortality, even if diagnosed early. The mainstay of early-stage breast cancer includes systemic chemotherapy and surgery, with or without radiation therapy.
15 Φεβ 2023 · Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancers and is characterized by an aggressive nature and a high rate of recurrence despite neoadjuvant and adjuvant chemotherapy.
TNBC presents a significant treatment challenge due to its aggressive nature and limited targeted therapy options 1, 2.Systemic multiagent chemotherapy improves long-term outcomes and is recommended for stage I–III TNBC disease, with most patients in the current era being treated with neoadjuvant chemotherapy 3.Anthracyclines and cyclophosphamide (AC) have typically constituted the ...
11 Ιαν 2022 · TNBC has a lot of clinical ramifications. In terms of new treatment methods, TNBC has lagged behind other types of breast cancer. There are not many options for treating this form of breast cancer because it is progressive.
14 Αυγ 2024 · The study aimed to assess the effectiveness and safety of dose-dense AC compared to every 3-week AC in patients with early-stage TNBC undergoing neoadjuvant chemotherapy plus pembrolizumab.
29 Οκτ 2019 · NACT is associated with increased rate of pathologic complete response (pCR), which has been associated with reduced risk of death and recurrence in all subtypes, including TNBC. 3 Residual cancer burden (RCB) after NACT has also been shown to predict disease recurrence and survival across all subtypes. 8 Additionally, neoadjuvant treatment ...
1 Αυγ 2012 · An evaluation of the combination of a standard chemotherapy (FEC100 followed by docetaxel) with panitumumab as neoadjuvant therapy of operable TNBC was recently reported with a pathological complete response rate of 65% .
